source
- Attovia Therapeutics raises $289 million in IPO to fund antibody-drug research for skin and inflammatory diseasesAttovia Therapeutics completed an IPO raising $289 million, selling 17 million shares at $17 each and valuing the company at $767 million. Shares will begin trading on Nasdaq under the ticker ATTO.…
- Novo Nordisk CEO says innovation is essential as pipeline faces setbacksDuring Novo Nordisk's second-quarter earnings call, CEO Maziar Mike Doustdar said that failure is a normal part of drug development and emphasized that the company's survival depends on continual i…